By second-guessing FDA safety determinations, the Fifth Circuit challenges the Supreme Court to restore agency deference.
Experts discuss how regulators can protect consumers from aggressive collection practices.
Anti-abortion advocates take aim at FDA approval and regulation of the abortion drug mifepristone, threatening access nationwide.
FDA’s approach to evidence-based decision-making may not be addressed to the right people.
Experts contend that FDA clinical trials fail to ensure adequate consideration of women’s health needs.
Exploring FDA’s toolkit for encouraging study sponsors to meet diversity goals.
Scholars discuss the lack of uniform standards for health care provided behind bars.
States should require doctors to seek informed consent before performing pelvic exams on anesthetized women.
Federal regulators seek to expand safe harbors for provider care coordination arrangements.
Scholars argue that FDA should use larger health data sets in its approval process for high-risk drugs.
A proposed requirement to display drug list prices in advertisements draws controversy.
Federal health agencies should work together to address public health problems.